INTRODUCTION: This study primarily sought to evaluate the risk factors for toxic megacolon development and treatment outcomes in Clostridium difficile-positive COVID-19 patients, secondarily to determining predictors of survival. METHODS: During the second COVID-19 wave (May 2020 to May 2021), we identified 645 patients with confirmed COVID-19 infection, including 160 patients with a severe course in the intensive care unit. We selected patients with Clostridium difficile infection (CDI) (31 patients) and patients with toxic megacolon (9 patients) and analyzed possible risk factors. RESULTS: Patients who developed toxic megacolon had a higher incidence (without statistical significance, due to small sample size) of cancer and chronic obstructive pulmonary disease, a higher proportion of them required antibiotic treatment using cephalosporins or penicillins, and there was a higher rate of extracorporeal circulation usage. C-reactive protein (CRP) and interleukin-6 values showed significant differences between the groups (CRP [median 126 mg/L in the non-toxic megacolon cohort and 237 mg/L in the toxic megacolon cohort; p = 0.037] and interleukin-6 [median 252 ng/L in the group without toxic megacolon and 1127 ng/L in those with toxic megacolon; p = 0.016]). As possible predictors of survival, age, presence of chronic venous insufficiency, cardiac disease, mechanical ventilation, and infection with Candida species were significant for increasing the risk of death, while corticosteroid and cephalosporin treatment and current Klebsiella infection decreased this risk. CONCLUSIONS: More than ever, the COVID-19 pandemic required strong up-to-date treatment recommendations to decrease the rate of serious in-hospital complications. Further studies are required to evaluate the interplay between COVID-19 and CDI/toxic megacolon.

Department of Surgery 1 Faculty of Medicine and Dentistry Palacky University Olomouc Hněvotínská 976 3 77515 Olomouc Czech Republic

Department of Surgery 1 University Hospital Olomouc 1 P Pavlova 185 6 77900 Olomouc Czech Republic

See more in PubMed

Olsen S.J., Chen M.-Y., Liu Y.-L., Witschi M., Ardoin A., Calba C., Mathieu P., Masserey V., Maraglino F., Marro S., et al. Early Introduction of Severe Acute Respiratory Syndrome Coronavirus 2 into Europe. Emerg. Infect. Dis. 2020;26:1567–1570. doi: 10.3201/eid2607.200359. PubMed DOI PMC

Onder G., Rezza G., Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA. 2020;323:1775–1776. doi: 10.1001/jama.2020.4683. PubMed DOI

WHO Coronavirus Disease (COVID-19) [(accessed on 24 February 2022)]. Available online: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200921-weekly-epi-update-6.pdf?sfvrsn=d9cf9496_6.

Huttner B.D., Catho G., Pano-Pardo J.R., Pulcini C., Schouten J. COVID-19: Don’t neglect antimicrobial stewardship principles. Clin. Microbiol. Infect. 2020;26:808–810. doi: 10.1016/j.cmi.2020.04.024. PubMed DOI PMC

Beović B., Doušak M., Ferreira-Coimbra J., Nadrah K., Rubulotta F., Belliato M., Berger-Estilita J., Ayoade F., Rello J., Erdem H. Antibiotic use in patients with COVID-19: A ‘snapshot’ Infectious Diseases International Research Initiative (ID-IRI) survey. J. Antimicrob. Chemother. 2020;75:3386–33090. doi: 10.1093/jac/dkaa326. PubMed DOI PMC

Cataldo M.A., Granata G., Petrosillo N. Clostridium difficile infection: New approaches to prevention, non-antimicrobial treatment, and stewardship. Expert. Rev. Anti. Infect. Ther. 2017;15:1027–1040. doi: 10.1080/14787210.2017.1387535. PubMed DOI

Furuya-Kanamori L., Marquess J., Yakob L., Riley T.V., Paterson D.L., Foster N.F., Huber C.A., Clements A.C.A. Asymptomatic Clostridium difficile colonization: Epidemiology and clinical implications. BMC Infect. Dis. 2015;15:516. doi: 10.1186/s12879-015-1258-4. PubMed DOI PMC

Cao W., Li T. COVID-19: Towards understanding of pathogenesis. Cell Res. 2020;30:367–369. doi: 10.1038/s41422-020-0327-4. PubMed DOI PMC

Horvat S., Rupnik M. Interactions Between Clostridioides difficile and Fecal Microbiota in in Vitro Batch Model: Growth, Sporulation, and Microbiota Changes. Front. Microbiol. 2018;9:1633. doi: 10.3389/fmicb.2018.01633. PubMed DOI PMC

[(accessed on 24 February 2022)]. Available online: https://www.mdcalc.com/atlas-score-clostridium-difficile-infection#evidence.

Khanna S., Kraft C.S. The interplay of SARS-CoV-2 and Clostridioides difficile infection. Future Microbiol. 2021;16:439–443. doi: 10.2217/fmb-2020-0275. PubMed DOI PMC

Stokes E.K., Zambrano L.D., Anderson K.N., Marder E.P., Raz K.M., El Burai Felix S. Coronavirus disease 2019 case surveillance—United States, January 22–May 30, 2020. MMWR Morb. Mortal. Wkly Rep. 2020;69:759–765. doi: 10.15585/mmwr.mm6924e2. PubMed DOI PMC

Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J., Wang B., Xiang H., Cheng Z., Xiong Y., et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus—Infected Pneumonia in Wuhan, China. JAMA. 2020;323:1061–1069. doi: 10.1001/jama.2020.1585. PubMed DOI PMC

Han C., Duan C., Zhang S., Spiegel B., Shi H., Wang W., Zhang L., Lin R., Liu J., Ding Z., et al. Digestive Symptoms in COVID-19 Patients With Mild Disease Severity: Clinical Presentation, Stool Viral RNA Testing, and Outcomes. Am. J. Gastroenterol. 2020;115:916–923. doi: 10.14309/ajg.0000000000000664. PubMed DOI PMC

Leffler D.A., Lamont J.T. Clostridium difficile infection. N. Engl. J. Med. 2015;372:1539–1548. doi: 10.1056/NEJMra1403772. PubMed DOI

Pérez-Cobas A.E., Moya A., Gosalbes M.J., Latorre A. Colonization Resistance of the Gut Microbiota against Clostridium difficile. Antibiotics. 2015;4:337–357. doi: 10.3390/antibiotics4030337. PubMed DOI PMC

Smits W.K., Lyras D., Lacy D.B. Clostridium difficile infection. Nat. Rev. Dis. Primer. 2016;2:16020. doi: 10.1038/nrdp.2016.20. PubMed DOI PMC

Brown K.A., Khanafer N., Daneman N., Fisman D.N. Meta-Analysis of Antibiotics and the Risk of Community-Associated Clostridium difficile Infection. Antimicrob. Agents Chemother. 2013;57:2326–2332. doi: 10.1128/AAC.02176-12. PubMed DOI PMC

Desai J., Elnaggar M., Hanfy A.A., Doshi R. Toxic Megacolon: Background, Pathophysiology, Management Challenges and Solutions. Clin. Exp. Gastroenterol. 2020;13:203–210. doi: 10.2147/CEG.S200760. Erratum in Clin. Exp. Gastroenterol. 2021, 19, 309–310. PubMed DOI PMC

Trudel J.L., Deschênes M., Mayrand S., Barkun A.N. Toxic megacolon complicating pseudomembranous enterocolitis. Dis. Colon Rectum. 1995;38:1033–1038. doi: 10.1007/BF02133974. PubMed DOI

Rubin M.S., Bodenstein L.E., Kent K.C. Severe Clostridium difficile colitis. Dis. Colon. Rectum. 1995;38:350–354. doi: 10.1007/BF02054220. PubMed DOI

Shetler K., Nieuwenhuis R., Wren S.M., Triadafilopoulos G. Decompressive colonoscopy with intracolonic vancomycin administration for the treatment of severe pseudomembranous colitis. Surg. Endosc. 2001;15:653–659. doi: 10.1007/s004640080104. PubMed DOI

Granata G., Bartoloni A., Codeluppi M., Contadini I., Cristini F., Fantoni M., Ferraresi A., Fornabaio C., Grasselli S., Lagi F., et al. The Burden of Clostridioides Difficile Infection during the COVID-19 Pandemic: A Retrospective Case-Control Study in Italian Hospitals (CloVid) J. Clin. Med. 2020;9:3855. doi: 10.3390/jcm9123855. PubMed DOI PMC